The Lymphoma Channel is supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2021 | Predicting tipifarnib response in T-cell NHL
Francine Foss, MD, Yale University School of Medicine, New Haven, CT, presents findings from a Phase 2 study (NCT02464228) of tipifarnib, a farnesyltransferase inhibitor, in T-cell non-Hodgkin lymphomas (NHL). Certain biomarkers such as CXCL12 and KIR3DL2 expression have accurately predicted responses to tipifarnib, and tipifarnib was found to be especially efficacious in patients with angioimmunoblastic T-cell lymphoma (AITL). Prof. Foss additionally highlights how tipifarnib can bridge patients to allogeneic stem cell transplantation. This interview took place at the 63rd ASH Annual Meeting and Exposition congress in Atlanta, GA.
